Feb 4, 2009 -Novo Nordisk and Sciele Pharma, Inc., a Shionogi Company, today announced the availability of PrandiMet (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the short-acting secretagogue repaglinide and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the United States.
The details can be read here.
No comments:
Post a Comment